FindTrial
Sign In

Does combined used of Pentoxifylline and Tocotrienol help patients with thin endometrium

The effect of Pentoxifylline and Tocotrienol in endometrial rejuvenation in the case of thin endometrium opting for frozen embryo transfer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/10/058640
Enrollment
264
Registered
2023-10-13
Start date
Unknown
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O090- Supervision of pregnancy with history of infertility

Interventions

Intervention1: Pentoxifylline plus Tocotrienol: Pentoxifylline 400mg oral twice daily plus Tocotrienol 300mg oral once daily. Three to six months before embryo transfer Control Intervention1: Standa

Sponsors

Indira IVF Hospital Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: (a) History of one cancelled embryo transfer due to thin endo (b) Age 25–45 years, (c) Body mass index (BMI) 18.5 to 29.9 kg/m2 (d) Recipients of Donor oocyte & Donor embryo.

Exclusion criteria

Exclusion criteria: (a) Presence of uncontrolled endocrine disorders (uncontrolled diabetes mellitus/ hyperprolactinemia, thyroid dysfunction, (b) Previous major uterine surgery (c) Previous hysteroscopic surgery (d) Adenomyosis (e) Endometriosis (f) Untreated hydrosalpinx (g) RIF (h) Cotreatment with any Nitric Oxide donor (i) Patients with bleeding disorder or those who are at increased risk of retinal bleeding, peptic ulcer, or preoperative patients (j) Patients with Renal Impairment: Patients with creatinine clearance less than 30 mL/min (k) Allergy to xanthine derivatives, e.g., caffeine, theophylline, theobromine (l) Acute myocardial infarction or severe coronary disease due to increased risk of myocardial demand (m) Severe liver disease (Child pugh class C) or cirrhosis (n) Pregnancy and Breastfeeding (o) bleeding disorders (altered prothrombin time (p) Co-administration with (q) other antihypertensive drugs (r) Glibenclamide or metformin (s) other theophylline derivatives (t) Co- treatment with Aspirin

Design outcomes

Primary

MeasureTime frame
Endometrial thicknessTimepoint: before day 14-day 21 of HRT—

Secondary

MeasureTime frame
Biochemical PregnancyTimepoint: 14 days after embryo transfer;Clinical PregnancyTimepoint: 4 weeks after embryo transfer;Ongoing pregnancyTimepoint: 18 wks after embryo transfer plus 2 wks.—

Countries

India

Contacts

Public ContactDr Nihar Ranjan Bhoi

Indira IVF hospital Private Limited

drnihar.bhoi@indiraivf.in

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026